Sillajen Biotherapeutics, Inc.

Onyx Pharmaceuticals, Inc.

Sillajen, Inc.

Jennerex, Inc.

Ignite Immunotherapy, Inc.

Jennerex Biotherapeutics Ulc

David H Kirn

John Cameron Bell

Caroline Breitbach

Anne Moon

Steve H Thorne

Yu Kyoung Lee

Tae-Ho Hwang

Liliana Maruri Avidal

Mi-kyung Kim

Joseph John Binder

Michael Dale Eisenbraun

James R Bischoff

Julie Nye

Douglas Hanahan

Lelia Ng

Angelica Williams

Sharon Horn

Clare Lees

Prajit Limsirichai

Adam Sampson-Johannes

Mi-Kyung Kim

The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.

Recombinant vaccinia virus and methods of use thereof

The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.

Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.

Methods and compositions for production of vaccina virus

The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

Methods and compositions for production of vaccinia virus

Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1&#xd7;10infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

Oncolytic vaccinia virus cancer therapy

The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.

Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses

Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.

Oncolytic vaccinia virus combination cancer therapy

The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.

Methods and compositions concerning poxviruses and cancer

Growing community of inventors

Mill Valley, CA, United States of America

David H Kirn